CMHC Pulse Blog

Two new insulin formulations were recently granted FDA approval: Tresiba® (insulin degludec), a long-acting insulin analog that can be administered once daily any time of day, and Ryzodeg®, a combination of insulin degludec and rapid-acting insulin aspart that is taken once or twice per day with any main meal. Both are indicated for adults with type 1 and 2 diabetes.

The approvals add to a growing list of insulin options for patients with diabetes. Toujeo® (insulin glargine U300) was approved earlier this year and Afrezza®, the only inhaled insulin available in the US, reached pharmacies in February. Learn more about these newest options and how they can help you customize your patients’ insulin regimens at the 10th Annual CMHC. On Friday, October 23, Dr. Matthew Riddle will chair the symposium, “Paving the Way to Patient Acceptance, Adherence and Satisfaction: The Role of Next-Generation Insulin Therapies,” and Dr. Anne Peters will chair “The Evolution of Insulin Therapy: New Developments in Treatment, Technology, and Methods of Administration” on Saturday, October 24.

Read more about the latest approvals here.


Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.